Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)

NCT05922124 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT05922124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05922124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)
Lead sponsor
Rambam Health Care Campus
Phase
Phase 4
Overall status
Recruiting
Start date
September 1, 2024
Completion date
September 30, 2026
Enrollment
734 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acinetobacter bacteremia, acinetobacter pneumonia, carbapenem resistant bacterial infection